Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an experimental oral therapy targeting acute myeloid leukaemia (AML) and high-risk myelodysplastic syndromes (MDS). The BRAMLIE trial will assess the safety, pharmacokinetics and preliminary efficacy of AMX-883 as a monotherapy in approximately 54 participants. The US Food and Drug Administration authorised […]
The post Amphista doses first patient in AML trial of protein degrader appeared first on Pharmafile.